Press release
FDA Approvals in Full Swing, Prefilled syringes Market Gets a Boost
Prefilled Syringes Market- Allied Market Research
Get the sample PDF brochure of prefilled syringes market study at: https://www.alliedmarketresearch.com/request-sample/444
The enormous market potential has been identified by many manufacturing companies. German healthcare device producer Gerresheimer started establishing the fourth manufacturing line for prefilled syringes to its plant situated in Bünde. The drug contamination risk reducing syringes have gained popularity across the world. The U.S. Food & Drug Administration (FDA), the leading authority that approvals new drugs, products, and technologies in the medical sector in the U.S. has recently approved many prefilled syringes for various conditions. Following are some of the approved products for different health conditions:
Adamis Epinephrine Prefilled Syringe:
Adamis Pharmaceuticals Corporation received an FDA approval for its Epinephrine prefilled syringe for treatment of allergic reactions including anaphylaxis. It is a 0.3 mg prefilled single dose syringe (PFS). It also received a trade name of Symjepi™. This offers two single dose syringes of epinephrine(adrenaline), which is a drug of choice for instant administration in the acute anaphylactic reactions to insect bites or stings. Moreover, this dose can be administrated in the allergic reaction to foods, drugs, and other allergens. Idiopathic or exercise-induced anaphylaxis can also be treated with this drug.
Dr. Dennis J. Carlo, President and CEO of Adamis, stated, “We are very excited by this approval, and at the same time, are already preparing to submit our second NDA to the FDA. This second submission is for the junior version of Symjepi. We are committed to helping patients by providing them with additional therapeutic choices.”
He also stated that Symjepi would become the favorite option for patients and medical professionals owing to small size, low cost, and user-friendly design. The company has been seeking commercialization options and discussions with potential partners have been conducted to widen patient access.
Genentech’s Lucentis 0.3 mg:
Genentech revealed that the FDA has approved Lucentis 0.3 mg prefilled syringe for treatment of diabetic retinopathy condition with or without diabetic macular edema(DME). The company stated that this syringe has been made available from the second quarter of 2018. This syringe is made up of borosilicate glass and a single-use sterile & sealed tray is used to package. It eliminates a lot of preparation work of medical professionals and enables them to administrate Lucentis instantly. Physicians do not have to pull the medicine from vial, disinfect it, or attach the needle with the help of administration method. The FDA has also approved Lucentis 0.5 mg prefilled syringe for macular edema after retinal vein occlusion, wet age-related macular degeneration, and myopic choroidal neovascularization.
“With the PFS, physicians will have a new option for administering Lucentis to the hundreds of thousands of people in the U.S. diagnosed with either wet AMD or macular edema after RVO,” said Sandra Horning, MD, chief medical officer and head of global product development at Genentech. “Today’s approval of the Lucentis 0.3 mg prefilled syringe reinforces our commitment to advancing therapy for those impacted by this vision-threatening disease.”
The FDA has also approved Lucentis 0.5 mg prefilled syringe for macular edema after retinal vein occlusion, wet age-related macular degeneration, and myopic choroidal neovascularization. The press release on approval of Lucentis 0.3 mg syringe also stated that physicians and medical professionals can take off the syringe cap, connect an injection needle to syringe, and adjust the dose prior to administration. The 0.3 mg syringe needs to be prefilled with an anti-VEGF agent. This agent has been approved the FDA for treatment of diabetic retinopathy and DME.
Philip Storey, MD, MPH at the Wills Eye Conference and colleagues found that anti-VEGF injection administrated via prefilled syringe lowers the risk of endophthalmitis as compared to administration through the conventional method of injection. Storey said, “The odds of endophthalmitis infection was 2.5 times higher with the conventional medication than with the prefilled medication.”
Have a question? Connect to analyst at: https://www.alliedmarketresearch.com/connect-to-analyst/444
After careful consideration and pool of data, Storey and team discovered that an incidence of endophthalmitis when injection was given through prefilled syringes was one in 9,050, while it was one in 3,413 through the conventional method of injection. This showed that prefilled syringes offer a safer way to administrate drugs in patients. The industry has been riding on a trend of innovation to address concerns regarding safety of conventional way of injection. More innovative products will be launched and approved by the FDA in coming years.
About Us
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions.? AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.
Contact:
Shriram Dighe
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
Toll Free: +1-800-792-5285
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1?855?550-5975
help@alliedmarketresearch.com
Web: https://www.alliedmarketresearch.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release FDA Approvals in Full Swing, Prefilled syringes Market Gets a Boost here
News-ID: 1139118 • Views: …
More Releases from Allied Market Research
Glueless Wigs Market 2026 : Why You Should Invest In This Market ?
The popularity of glueless wigs among people of all ages & genders is increasing rapidly. Glueless wigs come pre-attached with combs, bands, and straps for attachment to your head. This type of wig is very easy to fix and remove.
According to the report, the global glueless wigs market was valued at $719.2 million in 2022, and is projected to reach $1.3 billion by 2032, registering a CAGR of 6.3% from…
Africa Costume Jewelry Market Projected Expansion to Receive Overwhelming Hike I …
The Africa costume jewelry market is driven by factors such as rise in fashion conscious consumers and innovation in jewelry design and integration of African culture in the jewelry. However, limited supply chain infrastructure and less durability of costume jewelry restrict the market growth. Moreover, the growth of the tourism industry offers new opportunities in the coming years.
Costume jewelry, in contrast to more costly materials such as gold, diamonds, platinum,…
Medical Fluid Bag Market to reach $ 6,057.60 million by 2030 registering a CAGR …
The Medical Fluid Bag Market is experiencing sustained growth as healthcare systems worldwide continue to expand and modernize. These bags - essential for storing and administering medical fluids such as blood, intravenous (IV) solutions, nutritional feeds, and drainage fluids - are indispensable across clinical settings including hospitals, clinics, blood banks, and home care environments.
Download Sample Report PDF- https://www.alliedmarketresearch.com/request-sample/11237
Market Size & Forecast
Recent industry estimates highlight the robust growth trajectory of the…
Sharing Accommodation Market 2026 : Projected to Surpass $235.7 Billion by 2032
Allied Market Research published a report, titled, "Sharing Accommodation Market by Type (Business to Consumer (B2C), Business to Business (B2B), and Peer to Peer (P2P)), and Application (Generation Z, Millennials, Generation X, and Boomer), Opportunity Analysis and Industry Forecast, 2023-2032." According to the report, The global sharing accommodation market size was valued at $120.8 billion in 2022, and is projected to reach $235.7 billion by 2032, growing at a CAGR…
More Releases for FDA
DreaMed receives 5th FDA Clearance
TEL AVIV, Israel: DreaMed Diabetes LTD. ("DreaMed" or the "Company"), developer of the endo.digital Clinical Decision Support System announced today that it has received its 5th U.S Food and Drug Administration (FDA) clearance that expands the scope of AI enhanced treatment recommendations to patients on fixed meal insulin regimens. endo.digital is the first decision support system that has been cleared to assist healthcare providers in the management of diabetes…
FDA Compliant Blood Storage and Preservation
Accsense Monitoring System Automates Data Archive and Alarming
CAS DataLoggers provided the temperature alarming and monitoring system to a hospital blood bank looking to replace their old paper chart recorders as they became unreliable and spare parts were harder to find. For proper blood storage and preservation, the lab’s medical units needed to maintain storage temperatures between 2°C to 6°C (36°F to 43°F), given the perishability of blood components. The facility…
FDA grants orphan drug status to Vicore
US Food and Drug Administration has awarded Vicore Pharmaceuticals with orphan Drug designation for the treatment of Idiopathic Pulmonary Fibrosis (IPF). FDA’s Orphan Drug Designation program provides certain incentives for companies developing therapeutics to treat rare diseases or conditions, defined as those affecting less than 200,000 individuals in the U.S. A drug candidate and its sponsor must meet several key criteria in order to qualify for, and obtain, orphan drug…
New FDA Design Control Training Courses
Salt Lake City, Utah - February 23 2017 - Procenius Consulting is a medical device consulting firm specializing solely in medical device design controls regulation (21 CFR 820.30).
Announcing New Design Control Training Courses
Procenius Consulting has just launched two new training courses covering basic and advanced topics of medical device design control regulation. These courses focus on compliance, practical implementation and industry best practices techniques for developing or improving a…
fda online training
GRC Training Solutions provides end-to-end FDA compliance solutions for those companies who want to maximize security, minimize operational costs, improve staff productivity and stay on top of all their compliance documentation.
GRC Training Solutions boasts a team of experts and specialists who have a proven track record in working with the biotechnology, medical device, diagnostic and pharmaceutical fields. Our team will work with you closely and develop solutions that meet…
FDA online training
Description:
Device firms, establishments or facilities that are involved in the production and distribution of medical devices intended for use in the U.S are required to register annually. Most establishments that are required to register with the FDA are also required to list the devices that are made there and the activities that are performed on those devices. Initially, FDA issued a 28-page Proposed Rule that would amend its regulations regarding…
